169 Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Bought by Opal Wealth Advisors LLC

Opal Wealth Advisors LLC bought a new position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 169 shares of the pharmaceutical company’s stock, valued at approximately $82,000.

Other large investors have also bought and sold shares of the company. Tritonpoint Wealth LLC lifted its stake in shares of Vertex Pharmaceuticals by 15.9% in the 1st quarter. Tritonpoint Wealth LLC now owns 604 shares of the pharmaceutical company’s stock valued at $293,000 after purchasing an additional 83 shares during the period. Ipswich Investment Management Co. Inc. lifted its stake in shares of Vertex Pharmaceuticals by 10.2% in the 1st quarter. Ipswich Investment Management Co. Inc. now owns 5,518 shares of the pharmaceutical company’s stock valued at $2,675,000 after purchasing an additional 510 shares during the period. New Century Financial Group LLC lifted its stake in shares of Vertex Pharmaceuticals by 16.9% in the 1st quarter. New Century Financial Group LLC now owns 967 shares of the pharmaceutical company’s stock valued at $469,000 after purchasing an additional 140 shares during the period. CVA Family Office LLC lifted its stake in shares of Vertex Pharmaceuticals by 11.5% in the 1st quarter. CVA Family Office LLC now owns 427 shares of the pharmaceutical company’s stock valued at $207,000 after purchasing an additional 44 shares during the period. Finally, Salem Investment Counselors Inc. lifted its stake in shares of Vertex Pharmaceuticals by 23.6% in the 1st quarter. Salem Investment Counselors Inc. now owns 320 shares of the pharmaceutical company’s stock valued at $155,000 after purchasing an additional 61 shares during the period. 90.96% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on VRTX. Leerink Partners reissued a “market perform” rating and issued a $503.00 price objective (down from $550.00) on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 6th. Scotiabank dropped their price objective on Vertex Pharmaceuticals from $450.00 to $442.00 and set a “sector perform” rating on the stock in a research note on Tuesday, May 6th. Bank of America boosted their target price on Vertex Pharmaceuticals from $555.00 to $567.00 and gave the company a “buy” rating in a research report on Monday, March 31st. JPMorgan Chase & Co. boosted their target price on Vertex Pharmaceuticals from $512.00 to $515.00 and gave the company an “overweight” rating in a research report on Tuesday, May 6th. Finally, Leerink Partnrs lowered Vertex Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, May 6th. Fourteen investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $515.04.

Vertex Pharmaceuticals Stock Performance

Shares of VRTX opened at $455.45 on Monday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.35 and a current ratio of 2.69. The stock has a 50 day moving average price of $462.54 and a two-hundred day moving average price of $460.10. The firm has a market capitalization of $116.96 billion, a P/E ratio of -207.02, a P/E/G ratio of 2.11 and a beta of 0.41. Vertex Pharmaceuticals Incorporated has a 52 week low of $377.85 and a 52 week high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 earnings per share for the quarter, missing analysts’ consensus estimates of $4.29 by ($0.23). Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%. The business had revenue of $2.77 billion during the quarter, compared to analysts’ expectations of $2.85 billion. During the same quarter in the previous year, the firm earned $4.76 EPS. Vertex Pharmaceuticals’s quarterly revenue was up 2.6% on a year-over-year basis. Equities analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.